Orencia (abatacept) / Ono Pharma, BMS, Simcere - LARVOL DELTA

Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies. (PubMed, Diabetes Res Clin Pract) - "We review adult and adolescent evidence for targeted immunomodulators, including teplizumab, abatacept, rituximab, low-dose anti-thymocyte globulin, ustekinumab, golimumab, baricitinib and alefacept, as well as β-cell-directed agents such as verapamil and imatinib, and discuss emerging HLA- and autoantibody-defined endotypes that may predict response. Collectively, current evidence supports routine autoimmune diabetes screening in adults with new-onset diabetes."

Journal • Review • Diabetes • Immunology • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma (ASH 2025) - "As conditioning regimens, 12 patients received Fludarabine/Busulfan, and 5 patients received Fludarabine/Melphalan...For GVHD prophylaxis, 6 patients received Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil (MMF); 9 patients received Thymoglobulin, Tacrolimus, and MMF; 1 patient received Thymoglobulin, Sirolimus, and MMF; 1 patient received Tacrolimus, Methotrexate, and Abatacept...Limitations of the outcome data include a relatively small population that underwent Allo-HCST, likely lower than the true number of patients with SPM following Auto-HSCT due to them either not returning to the center or opting against Allo-HSCT for treatment. This data adds to the collective understanding of the associated risks and benefits of Allo-HSCT for treatment of hematological SPM following Auto-HSCT for MM."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • Transplantation • TP53

Long-term follow-up of novel post-transplant cyclophosphamide (PTCy) and abatacept (aba) graft-versus-host disease (GVHD) prophylaxis regimen compared to tacrolimus and methotrexate. (ASH 2025) - "This exploratory analysis found the intervention, PTCy + aba GVHD prophylaxis, at 2-5 year long-term follow-up was associated with sustained decreased cGHVD, with no difference in cGRFS and OS compared to the Control arm. There was a trend for more relapses on the PTCy + aba arm. This was confounded by small sample size and the fact that patients were stratified based on GVHD and not relapse risk, resulting in more patients with high-risk disease on the intervention arm.QoL at long-term follow-up was not different between arms, with results also limited by small sample size and confounded by non-response bias."

Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Results of abatacept addition to post transplant cyclophosphamide-based GVHD prophylaxys in allogeneic hematopoyetic stem cell transplantation (ASH 2025) - "All patients received peripheral blood as graft source and all patients received GVHD prophylaxis with ABA in combination with PTCY, tacrolimus, and mycophenolate mofetil...Reduced-intensity conditioning regimens were used in the majority of patients in both cohorts (88.2% vs 93.4%, p=0.5), most commonly conditioning included busulfan-fludarabine or busulfan-cyclophosphamide-fludarabine. In the +56 cohort, 2 patients received clofarabine-melphalan, according to internal protocol, due to disease persistence prior to transplant.With a median follow-up of 15.7 months (range 7.4–31.1), estimated 1-year PFS and OS were 66% (IC95%= 0.5-0.7) and 72% (IC95%= 0.5-0.8)... Our experience suggests, compared with previous analysis ( P Fernandez-Caldas. EBMT 2024 ), that addition of ABA to PTCY-based prophylaxis, in peripheral blood stem cell setting, may reduce GVHD and allow early immunosuppression withdrawal without increasing GVHD rates, though sample size is limited."

Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • CTLA4

Early detection of emerging safety signals in GVHD prophylaxis agents using a 12-year faers "slope-watch" approach (ASH 2025) - "In addition to tacrolimus and cyclosporine, contemporary prophylaxis regimens employ sirolimus and everolimus, mycophenolate mofetil, methotrexate, post-transplant cyclophosphamide (PTCy), JAK inhibitors (ruxolitinib, baricitinib, tofacitinib), co-stimulation blockade with abatacept, gut-homing integrin antagonism via vedolizumab, and the ROCK2 inhibitor belumosudil. Sequential IC-Δ offers a robust, forward-looking pharmacovigilance framework that identifies adverse event acceleration 12–24 months before regulatory action. By emphasizing directional change and incorporating a simple confidence approximation, this approach enhances early signal detection in large safety datasets. Integration with electronic health records, regulatory pipelines, and interactive dashboards could further streamline horizon scanning and improve patient safety in GVHD prophylaxis."

Clinical • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Dyslipidemia • Graft versus Host Disease • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock

Targeted GvHD prophylaxis: Vedolizumab in the GvHD prevention regime with post-transplant cyclophophospamide, abatacept, calceneurin inhibitors in adults with hematologic disease: Result prospective study (ASH 2025) - "This study evaluated the efficacy of a four-drug regimen combining vedolizumab (300 mg IV on days -1, +14, +28), tacrolimus (0.03 mg/kg from day -1 to +120), abatacept (10 mg/kg IV on days -1, +5, +14, +28, +60, +90), and post-transplant cyclophosphamide (PTCy) (50 mg/kg on days +3, +4 in 60.7% of patients). Favorable safety without compromising engraftment. Warranting further validation in randomized trials."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation (ASH 2025) - P2 | "The approach has expandedtransplant access for patients lacking 8/8 human leukocyte antigen (HLA)-matched donors, particularlythose from racially and ethnically diverse Background s. ACCESS (NCT04904588) evaluated the safety andefficacy of PTCy [50 mg/kg on days 3 (D3) and 4 (D4)], mycophenolate mofetil (MMF), and tacrolimus asGraft-versus-Host Disease (GvHD) prophylaxis in adult patients with hematologic malignancies receivingmyeloablative (MAC) or reduced intensity conditioning (RIC) followed by peripheral blood stem cells(PBSC) MMUD HCT (4-7/8 HLA match, considering HLA-A, -B, -C and -DRB1)...ACCEL-001 evaluatesthe safety and efficacy of 25 mg/kg PTCy, tacrolimus, and abatacept (D5, 14, 28, 56), and ACCEL-002evaluates outcomes using 25 mg/kg PTCy, tacrolimus, MMF, and ruxolitinib (5 mg twice daily starting D30and initiating taper at D180 if no GVHD, then discontinue by D270) as GvHD prophylaxis following MMUDPBSC HCT using MAC or RIC conditioning...The study will..."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Transplantation • HLA-B • HLA-C • HLA-DRB1

Haploidentical donor regulatory T cells and memory T cells are safe and effective in children with refractory graft-versus-host disease with concurrent viral infections (ASH 2025) - "All patients had received multiple lines of priorIST, including glucocorticosteroids, cyclosporine, and biologics (tocilizumab,infliximab, abatacept, etarnecept, vedolizumab)...Nine patients recieved lymphodepletion with cyclophosphamideat 400 mg/m2... Combined haploidentical Treg and memory T cell therapy, with memory T cellsgenerated solely by flow cytometry-based sorting, is feasible and safe in pediatricpatients with refractory GVHD and viral infections. This approach resulted incomplete IST withdrawal and GVHD control in the majority of evaluable patients at 1year. The promising outcomes in immune reconstitution and viral control supportfurther clinical investigation of this integrative cellular strategy for high-risk pediatrictransplant recipients."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • CD8 • FOXP3 • IL2RA • IL7R

Point of care anti-CD19 CAR-T for autoimmune diseases (ASH 2025) - P1/2 | "Two became treatment-free, while one continued low-dose methotrexate and abatacept.All RA patients showed marked decline in anti-CCP titers. POC anti-CD19 CAR-T therapy appears feasible, safe, and clinically beneficial in a subset of patients withsevere autoimmune diseases. Toxicity was manageable and dose-dependent. Higher inflammatoryburden may correlate with increased toxicity, underscoring the need for disease-specific riskstratification."

IO biomarker • CNS Disorders • Dermatomyositis • Hematological Malignancies • Immune Modulation • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Myasthenia Gravis • Myositis • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • IFIH1

Donor-derived CAR-T cells co-infused with the allogenic graft on the platform of T cell depletion or post-transplant cyclophosphamide in children with advanced B-cell neoplasms (ASH 2025) - "All patients had disease relapse after multiple lines of treatmentincluding previous HSCT(n=13), blinatumomab (n=22), inotuzumab (n=2), blinatumomab+inotuzumab(n=6) and CAR-T cell infusion(n=12)...The median proportion ofCD19-positive cells in the leukemic population was 100% (0–100%), while the median proportion of CD22-positive cells was 100% (36–100%).Fourteen (36%) pts received treosulfan-based myeloablative preparative regimen and TBI-based regimenwas used in 25 (64%) pts...Inthe PtCy group GVHD prophylaxis included abatacept, vedolizumab and CsA or baricitinib ResultsThere was no suspected conflict between the graft and CAR-T cells...We have documented CAR-T expansion and persistence. Prospective testing of theapproach is warranted."

CAR T-Cell Therapy • Clinical • Metastases • Post-transplantation • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Transplantation • CD22

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation (ASH 2025) - P1, P3 | "Use of ATG,alemtuzumab, cyclosporine A (CsA), and abatacept is excluded; other GvHD prophylaxis agents such aspost-transplant cyclophosphamide (PTCy) are permitted. There is an unmet medical need to maintain CR after allo-HCT, especially in AMLpatients with high risk factors or previous relapse. The MO-TRANS study aims to validate the therapeuticpotential of MOC in reducing relapse and GvHD in patients allografted for AML."

Clinical • P3 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Diabetes • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Macular Edema • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Transplantation • Uveitis

T cell receptor costimulation blockade effectively prevents acute graft versus host disease without reducing the size or diversity of the T cell immune repertoire (ASH 2025) - "Abatacept modulates T cell activity through CD28:CD80/86 costimulationblockade... Here we demonstrate that ABA did not reduce either the size or diversity of the T cellrepertoire in HCT recipients, despite its ability to control aGVHD. These results are consistent both withthe body of work establishing the mechanism of ABA as being immune modulating rather than T celldepleting, and with the intact protective immunity observed in ABA2. Notably, the higher number ofsingletons and higher richness at day 28 in those receiving ABA is consistent with our previous resultsdemonstrating that ABA preserves naïve T cells."

Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • CD80 • TRB

Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children (ASH 2025) - "Treatment options for steroiddependent, refractory/relapsed (r/r) wAIHA include rituximab, mycophenolate mofetil (MMF), and otherimmunosuppressants with splenectomy reserved for select cases...She was treated with steroids, rituximab, cyclosporine A (CSA), MMF, bortezomib,abatacept, sirolimus, and fostamatinib with multiple relpases...He was started on MMF anddaratumumab with remarkable recovery of hemolysis within 1 week; remains transfusion independent at1 month follow-up.Patient 4: A Caucasian girl diagnosed at 5 months of age with immunoglobulin G & complementmediated wAIHA initially responsive to prednisone and rituximab; she developed nephrotic syndromeand lupus nephritis by 1 year of age, complicated by renal failure. Multiple relapses of wAIHA weretreated with rituximab, cyclophosphamide, CSA, MMF, sirolimus, eculizumab, raviluzimab, andpegcetacoplan... In our experience daratumumab showed remarkable efficacy in treating r/r wAIHA inchildren. Responses were..."

Clinical • Anemia • Autoimmune Hemolytic Anemia • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Multiple Myeloma • Nephrology • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura

Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation (ASH 2025) - "ABA in combination with PTCy and TAC may improve overall survival and decrease the severity of acuteGVHD after HCT for hematological malignancies. Future prospective trials are in progress to confirmthese findings."

Combination therapy • Post-transplantation • Acute Graft versus Host Disease • Adult T-Cell Leukemia-Lymphoma • Chronic Graft versus Host Disease • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • TP53

Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse. (ASH 2025) - "(450 characters) We observed low treatment-related mortality and relapse rates in this cohort of patients with high-riskdisease and significant comorbidities. Reduced dose PTCy in combination with ABA and TAC was safe andtolerable. Immune reconstitution studies revealed diminished immune recovery in all lymphocytesubsets except NK cells."

Combination therapy • Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • CD4 • CD8

Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia (ASH 2025) - P=N/A, P1 | "Abatacept(CTLA4-Ig, 5 mg/kg) or an equivalent PBS was administered intraperitoneally 3 days prior to vectorinfusion, followed by twice-weekly maintenance dosing for 6 weeks...Prophylaxis CTLA4-Ig (5 mg/kg) was administered3 days prior to AAV vector (BBM-H803) infusion... Prophylaxis administration of CTLA4-Ig effectively suppresses anti-AAV Nab formationfollowing AAV gene therapy in hemophilia A patients, creating a potential immunological tolerancewindow for re-treatment."

Gene therapy • IO biomarker • Gene Therapies • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases • CD86

Enhancing graft-versus-host disease prophylaxis with modern strategies in matched-sibling or unrelated donor hematopoietic cell transplantation does not lead to higher relapse rates: A systematic review and meta-analysis of 15 randomized trials (ASH 2025) - "Pession et al (PMID 9630326) have shown in a randomized trial that a higher doseof cyclosporine may be associated with increased relapse rates...Five studies tested the addition of ATG; three, ATLG; three,PTCy; two, sirolimus; one each, abatacept or alemtuzumab... A total of 2,841 were screened, 49 were selected for full-text review, and 15 were included in thefinal analysis. Ten studies reported HR and 95%CI, while in five studies, the HR was estimated. All studiesprovided relapse incidence rates and 95%CI."

Retrospective data • Review • Acute Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation

ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen (ASH 2025) - P1/2 | "Background : We previously reported results of posttransplant cyclophosphamide (PTCy) and bortezomib(CyBor) combination in graft-versus-host disease (GvHD) prophylaxis following allogeneic blood andmarrow transplantation (BMT)...Conditioning regimens consisted of fludarabine (Flu) and busulfan (Bu)(2 days) or Flu, Bu (3 days) and thiotepa...GvHD prophylaxis included PTCy (50mg/Kg on days +3 and +4, bortezomib (1.3 mg/m² on days 0 and +3) and abatacept 10mg/Kg...One patient developed EBV-positive posttransplantlymphoproliferative disorder and responded to rituximab... These results confirm the feasibility and high efficacy of the ABC regimen as entirely CN andm-TOR inhibitor-free GvHD prophylaxis in allogeneic peripheral blood BMT. Viral reactivation wasmanageable. TRM was extremely low."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology

An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation (ASH 2025) - P1 | "We previouslydemonstrated that JAK1 inhibition with itacitinib is effective in preventing aGVHD and CRS, with excellentlong term GRFS and OS in a high-risk population undergoing allo-HCT...If safe, we will expand this approach to combine ruxolitinib and abatacept andreduce exposure to traditional immunosuppressants mycophenolate mofetil (MMF) and tacrolimus...All patients received standarddose post-transplant cyclophosphamide... Ruxolitinib with PB haplo-HCT appears safe, with no engraftment failure and promptengraftment. Severe CRS has not been seen in this trial. Rates of acute and chronic GVHD are low, and nopatients have relapsed during short follow-up to date."

Clinical • Cytokine release syndrome • P1 data • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Influenza • Pneumonia • Respiratory Diseases • Transplantation • CTLA4

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis (ASH 2025) - "Prescription refills in pharmacy claim records wereused to determine RUX and prednisone-equivalent CS dosing and treatment length. Line of therapy forcGVHD medications was based on claims for CS, belumosudil, abatacept, alemtuzumab, RUX, etanercept,hydroxychloroquine, ibrutinib, imatinib, interleukin-2, methotrexate, mycophenolate mofetil, pentostatin,and rituximab after cGVHD diagnosis... Patients treated with RUX for cGVHD in real-world clinical practice remained on treatmentfor a median of 8 months; 40.9% remained on RUX for 1 year and 21.3% for 2 years, suggesting long-termpersistence of safety and ongoing clinical benefit. Median time from earliest CS fill for cGVHD todiscontinuation or reduction to low-dose CS was 77 days. By the end of 1-year follow-up, 90% of patientsachieved discontinuation or reduction to low-dose CS."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • IL2

Discovery of the transcription factor ZNF683/hobit as a central regulator of pathogenic T cell proliferation in acute gvhd (ASH 2025) - "The ABA2 trial led to FDA approval of abatacept, a CD28:CD80/86costimulation blocker, as an adjunct to CNI/MTX that significantly prevented aGVHD... We have discovered a prominent role for the transcription factor HOBIT in regulatinginflammatory T cell alloproliferation that drives CNI/MTX breakthrough aGVHD, and its control withabatacept. These results are the first to identify HOBIT as a key regulator of alloreactivity, uncovering anew link between the mechanisms that harness the nascent T cell activation potential unleashed by ICI,and those that drive aGVHD. They nominate HOBIT as a critical regulator of multiple facets of T cellactivation, and underscore the central role that CD28:CD80/86 signaling plays in modulating HOBITexpression, and its downstream effects."

Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Inflammation • BCL2L11 • CD4 • CD8 • CD80 • IL2RA • MXRA7 • NR3C1

New Preclinical and Translational Approaches to Prevent GVHD (ASH 2025) - "Supported By Scientific Committee on Transplant Biology and Cellular Therapies We are in a new era of acute graft-versus-host disease (aGVHD) prevention, with the first drug, abatacept, now FDA approved to prevent this disease, and post-transplantation cyclophosphamide/Tacrolimus/MMF established as the new standard GVHD prevention strategy (over CNI/MTX) for patients undergoing transplantation following reduced intensity conditioning. She will also discuss new data on targeted agents that are designed to eliminate only alloreactive T cells, and their potential path to the clinic. The goal of this talk is to review the successes and tradeoffs of current prevention strategies, and how we might build on these current strategies to improve GVHD prophylaxis and outcomes for all transplant patients."

Preclinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology

New Age GVHD Prophylaxis Regimens: What Works for What Donor and Why (ASH 2025) - "These include post-transplantation cyclophosphamide (PTCy), Abatacept (Aba), and Vedolizumab (Vedo)-based approaches. Addtional options including JAK inhibitors, Sirolimus, Alpha-1 antitrypsin, ATG and Obinutuzumab maintenance will also be briefly reviewed."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) (ASH 2025) - "He highlights the effectiveness of post-transplant cyclophosphamide (PTCy), abatacept, and vedolizumab in preventing both acute and chronic GVHD. Therapies including JAK inhibitors, sirolimus, alpha-1 antitrypsin, anti-thymocyte globulin (ATG), and obinutuzumab maintenance are also reviewed, offering tailored options based on donor type and patient risk profiles.Dr...Agents like treosulfan provide safer conditioning with a favorable toxicity profile for individuals who are older, pediatric patients, or those with medical comorbidities. Additionally, methodologies for precise and targeted radiation delivery with minimal off-target effects are emerging. These advancements necessitate reexamination and harmonization of conditioning intensity stratification schemes for a more personalized and selective approach."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics • Transplantation • CD34

BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases. (PubMed, Br J Dermatol) - "For eczema, therapies such as dupilumab show limited evidence in also treating AA...For instance, baricitinib is licensed for both AD and AA, while upadacitinib is licensed for AD and is currently in phase III trials for AA. Amlitelimab, which targets the OX40 ligand pathway, is currently in phase III clinical trials for atopic dermatitis and in phase II trials for severe AA...In psoriasis, overlapping therapies include ustekinumab, approved for psoriasis and being studied for AA. As for patients with RA, tofacitinib is approved for moderate-to-severe disease and is also utilized in AA. Abatacept is a cytotoxic T lymphocyte-associated protein 4 (CTLA4) immunoglobin costimulatory modulator that attenuates the activation of T cells and is widely used in RA...The Global Registry of Alopecia areata disease Severity and treatment Safety (GRASS) UK is a prospective, multicentre, observational clinical registry designed to create harmonized datasets. These datasets aim to..."

Journal • Review • Alopecia • Atopic Dermatitis • CNS Disorders • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Rheumatology • Vitiligo • CTLA4